{"id":"cyclosporine-nova22007-0-05","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypertension"},{"rate":"5-15%","effect":"Nephrotoxicity"},{"rate":"5-10%","effect":"Diabetes mellitus"},{"rate":"5-10%","effect":"Hirsutism"},{"rate":"5-10%","effect":"Gingival hyperplasia"}]},"_chembl":{"chemblId":"CHEMBL406352","moleculeType":"Small molecule","molecularWeight":"1202.63"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cyclosporine works by binding to cyclophilin, which inhibits calcineurin's phosphatase activity. This prevents the dephosphorylation of NFAT, a transcription factor that regulates T-cell activation. As a result, T-cell activation is reduced, and the immune response is suppressed.","oneSentence":"Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:30:19.444Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of uveitis"}]},"trialDetails":[{"nctId":"NCT00328653","phase":"PHASE2, PHASE3","title":"Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2006-05","conditions":"Conjunctivitis, Vernal","enrollment":118},{"nctId":"NCT00739349","phase":"PHASE2","title":"NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2008-08","conditions":"Dry Eye","enrollment":132},{"nctId":"NCT00426023","phase":"PHASE3","title":"Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis","status":"COMPLETED","sponsor":"Campus Bio-Medico University","startDate":"2007-02","conditions":"Vernal Keratoconjunctivitis","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cyclosporine NOVA22007 0.05%","genericName":"Cyclosporine NOVA22007 0.05%","companyName":"Santen SAS","companyId":"santen-sas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation. Used for Treatment of uveitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}